Polymorphisms in the Factor VII Gene and the Risk of Myocardial Infarction in Patients with Coronary Artery Disease
- 14 September 2000
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 343 (11) , 774-780
- https://doi.org/10.1056/nejm200009143431104
Abstract
High plasma levels of coagulation factor VII have been suggested to be predictors of death due to coronary artery disease. Since polymorphisms in the factor VII gene contribute to variations in factor VII levels, such polymorphisms may be associated with the risk of myocardial infarction, which is precipitated by thrombosis. We studied a total of 444 patients, 311 of whom had severe, angiographically documented coronary atherosclerosis. Of these 311 patients, 175 had documentation of a previous myocardial infarction. As a control group, 133 patients with normal coronary arteriograms were also included. We measured the levels of activated factor VII and assessed three polymorphisms in the factor VII gene, one involving the promoter (A1 and A2 alleles), one involving the catalytic region (R353Q), and one involving intron 7. Each of the polymorphisms influenced factor VII levels. Patients with the A2A2 and QQ genotypes had the lowest levels of activated factor VII (66 percent and 72 percent lower, respectively, than the levels in patients with the wild-type genotypes). The frequencies of the various genotypes in the patients free of coronary artery disease were similar to those in the entire population of patients with coronary artery disease. In the latter group, there were significantly more heterozygotes and homozygotes for the A2 and Q alleles among those who had not had a myocardial infarction than among those who had had an infarction (P=0.008 for the presence of the promoter polymorphismand P=0.01 for the presence of the R353Q polymorphism by chi-square analysis). The adjusted odds ratio for myocardial infarction among the patients with the A1A2 or RQ genotype was 0.47 (95 percent confidence interval, 0.27 to 0.81). Our findings suggest that certain factor VII genotypes have a role in protection against myocardial infarction. This may explain why some patients do not have myocardial infarction despite the presence of severe coronary atherosclerosis.Keywords
This publication has 28 references indexed in Scilit:
- Coagulation Factors II, V, VII, and X, Prothrombin Gene 20210G→A Transition, and Factor V Leiden in Coronary Artery DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 1999
- Contribution of Factor VII Genotype to Activated FVII LevelsArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- The Arg 353 Gln Polymorphism Reduces the Level of Coagulation Factor VIIArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Polymorphisms of Factor V, Factor VII, and Fibrinogen GenesArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Functional Characterization of the Human Factor VII 5′-Flanking RegionPublished by Elsevier ,1996
- Genetic Dissection of Complex TraitsScience, 1994
- Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994
- The Pathogenesis of Coronary Artery Disease and the Acute Coronary SyndromesNew England Journal of Medicine, 1992
- A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1991
- HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDYThe Lancet, 1986